Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
HBW Insight is a single source of regulatory, legislative, legal and commercial news and insight connecting the dots across 3 sectors, including over the counter medicines, vitamins and dietary supplements, and cosmetics, which have increasing points of intersection, helping you to anticipate global challenges, risks, and opportunities.
How it helps
HBW Insight gives you the power to go behind the news stories to understand the implications of worldwide industry developments across three different but complementary consumer healthcare sectors, on your business.
How it works
A broad network of global expert analysts and journalists give you an insider’s perspective from tracking market events and their impacts from around the globe, to understand the potential impact of developments and trends. Plus, access to exclusive interviews with key opinion leaders and market movers. We also draw on the strength and expertise of the rest of the Pharma Intelligence family of analytical and market intelligence tools.
Health:
In-depth coverage and analysis of:
Beauty:
News and emerging issues in this rapidly evolving global sector on:
Wellness:
Up-to-the-minute news and the informed perspective on:
HBW Insight
15 Jan 2020
In addition to Sanofi, firms recalling OTC ranitidine products with documentation included in FDA's database updates through 9 January are Amneal Pharmaceuticals, Preferred Pharmaceuticals, which distributed products made by Amneal, and Granules India Ltd.
HBW Insight
By Tom Gallen 15 Jan 2020
Bayer has teamed up with skin microbiome specialist Azitra to develop consumer health products for a host of conditions.
HBW Insight
By Tom Gallen 09 Jan 2020
An interactive timeline of HBW Insight's coverage of the blossoming European CBD market in 2019. The timeline covers the main events of the year beginning with the European Commission's decision to classify CBD as a novel food, and ending on the filing of the first application for a synthetic form of the cannabis-derived ingredient.
HBW Insight
By Eileen Francis 08 Jan 2020
Perrigo's Ranir division purchased the brand, which includes a portfolio of antibacterial toothbrush protectors, children’s products and tongue cleaners, for an undisclosed amount from Bonfit America.
HBW Insight
By Eileen Francis 18 Dec 2019
Two CBD marketers warned by FDA in a recent crackdown are targeted in class action complaints alleging they made unsubstantiated health claims and mislabeled ‘illegal drug’ products as supplements. Complaints are a wake-up call to CBD wellness industry to ensure claims are substantiated, as the class action bar is on the prowl following the agency’s 15 warning letter blast in November.
HBW Insight
By David Ridley 18 Dec 2019
Reckitt Benckiser wants to give British parents more pain relief options for their teens and "tweens."
HBW Insight
By Malcolm Spicer 11 Dec 2019
Senate's Over-the-Counter Monograph Safety, Innovation, and Reform Act goes next for consideration by House, which has had a bill by the same title on its floor for a vote since it was passed by Energy and Commerce Committee in late June.
HBW Insight
By Ryan Nelson 11 Dec 2019
Farah Ahmed, president and CEO of the Fragrance Creators Association, discusses the trade group’s expansion in recent years beyond immediate regulatory and legislative concerns to a platform for robust member collaboration in the name of positively impacting the world.
HBW Insight
By Malcolm Spicer 06 Dec 2019
Recent statement that FDA has not found evidence supporting CBD as GRAS for use in human or animal food potentially points to NDI notifications as the only option manufacturers, marketers and other businesses will have to convince agency about safety for CBD and other hemp-derived substances used in dietary supplements.
HBW Insight
By Tom Gallen 06 Dec 2019
GSK has launched Flunase in Japan following the switch of fluticasone propionate. JSMI’s Toshi Tominaga gives his assessment of the product’s prospects as an OTC drug.
HBW Insight
By Ryan Nelson 28 Nov 2019
Industry advocates working to support GRASE determinations for eight UV filters are faced with a dilemma. They would like to share nonpublic studies with the FDA on a confidential basis – at least to get initial temperature readings from the agency as to the studies’ usefulness in addressing data gaps – but under the current OTC monograph framework, no such pathway exists.
HBW Insight
By Malcolm Spicer 27 Nov 2019
Before Congress de-scheduled hemp at end of 2018 and forced agency's hand on considering lawful use of ingredients derived from the plant in supplements and food, the floodgate for sales of the products was opened in 2013 by a DoJ policy change to de-emphasize enforcement of most federal marijuana laws.
HBW Insight
By Tom Gallen 22 Nov 2019
Aspirational OTC products such as probiotics are outstripping demand for traditional symptom relievers, IQVIA's Andy Tisman told the recent Ceuta International Conference. Consumer health players must adapt their portfolios to cater for the more health conscious, informed, and digitally-connected consumer, Tisman advises
Topic Business Strategies
HBW Insight
By Eileen Francis 13 Nov 2019
In latest study casting doubt on the nutrients' effect on chronic illness, researchers find vitamin D and fish oil ineffective in staving off type 2 diabetics' kidney failure. Editorial also published in JAMA says further research is needed to analyze the nutrients’ possible benefits to diabetics with chronic kidney disease.
Topic Clinical trials
HBW Insight
By David Ridley 13 Nov 2019
Following a landmark win against the German government for the Rx-to-OTC switch of desloratadine last month, Novartis has again secured a victory in the German Higher Court system, this time to continue marketing its Biosan probiotics range in the country.
UK
Richard specializes in
+27 year(s) experience
Washington DC, USA
Eileen specializes in
+20 year(s) experience
USA
Ryan specializes in
+16 year(s) experience
From discovery to patent expiry, and coverage spanning both ethical and generic drugs, Medtrack has you covered. Stay current on key financing, drug and biologics development and drug manufacturing information, all with a single tool.
Biomedtracker provides real-time analysis of major market-moving events in the pharma and biotech industries. With catalyst tracking and expert insights, you stay on top of breaking events, what’s in the drugs pipeline, upcoming milestones, clinical trial results and their impact on the markets you care about
Understand what’s happening in the market right now and what it means for the future of your business with news and insight from our team of journalists and analysts. Scrip is essential for anyone making commercial decisions in the pharmaceutical industry.
Looking for more products Product Finder
Request a Trial
Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.
How can we help you?
Our team is always happy to hear from you. Please call us at:
Pharma Report Store
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now:
